Suono Bio gets Fujifilm investment for its second-generation drug delivery tech, names new CEO

Drugs and money
Fujifilm is investing in Suono Bio’s second-generation drug delivery technology. (Getty/LIgorko)

Japan’s Fujifilm is investing (PDF) in Suono Bio’s second-generation drug delivery technology that uses speedy, formulation-independent application of therapeutics that include biologics and gene therapies.

Terms and the amount of the investment by the Tokyo-based company weren’t disclosed.

Suono Bio uses tech developed in the MIT laboratory of Robert Langer. The technology has shown preclinical activity in a scope of diseases using a diverse set of therapeutics, the company said.

INDUSTRY RESEARCH

Veeva 2019 Unified Clinical Operations Survey

Share your thoughts in this quick survey. The first 50 qualified respondents will receive a $5 Amazon gift card, and, in appreciation for your time, all qualified survey respondents will be entered in a drawing to win a $50 Amazon gift card.

“Fujifilm has deep technical expertise and offers the chance to accelerate our development by working closely with their scientists and engineers in the future,” Langer said in a statement.

In a separate announcement, Suono Bio announced that it named Lisa Ricciardi as chief executive. Prior to joining the company, Ricciardi has worked for a variety of organizations, including Pfizer, Medco, Foundation Medicine and Essex Woodlands.

“The addition of Lisa to the team marks an important milestone for Suono Bio, particularly as we prepare for our entry to the clinic,” Dr. Carl Schoellhammer, the company’s founding chief executive, said in a statement.

Schoellhammer will take on the role of COO and serve on the board.